Issue 4
-
Presenters share latest insights from research into the tumor-host ecosystem
Monday’s Plenary Session featured (clockwise, from top left) Serena Nik-Zainal, MD, Ross Levine, MD, Jérôme Galon, PhD, and Garry P. Nolan, PhD.
-
Panel to discuss how precision medicine can move toward health equity
(Clockwise, from top left) Luis Carvajal-Carmona, PhD, Tiffany Wallace, PhD, Nicole Coggins, PhD, Nora M. Navone, MD, PhD, and Kevin L. Gardner, PhD, took part.
-
Highlights from the Program Chair: Tuesday, April 13
Program Committee Chair Charles Swanton, MBPhD, FAACR, shares some of his selections from the day’s sessions to help plan your Annual Meeting experience.
-
New Drugs on the Horizon sessions offer first disclosures of novel agents
Investigators in three related sessions shared details about 12 small molecules and biologics in or about to be tested in phase I clinical trials.
-
Presidential Address: Using the immune system to fight melanoma
Antoni Ribas, MD, PhD, FAACR, discussed how researchers are working to change the treatment paradigm for patients with melanoma and reflected on his term as AACR President.
-
Forum focuses on dysfunctional, exhausted T Cells
(Clockwise, from top left) Andrea Schietinger, PhD, Daniela S. Thommen, MD, PhD, E. John Wherry, PhD, and Rachel C. Lynn, PhD, presented data that should help shape understanding of T cell function.
-
Cancer research starts looking toward the microbiome for biomarkers and treatment
(From left) Jennifer A. Wargo, MD, MMSc, Rob Knight, PhD, and Siew C. Ng, PhD, discussed this emerging topic and will have a live panel session on Wednesday, April 14.
-
Plenary to take closer look at the evolution of cancer biology and therapies
Tuesday’s plenary will feature (clockwise, from top left) Olufunmilayo I. Olopade, MD, FAACR, Tony Hunter, PhD, FAACR, Dennis J. Slamon, MD, PhD, FAACR, and William George Kaelin Jr., MD, FAACR.